Previous 10 | Next 10 |
home / stock / biovf / biovf news
STOCKHOLM , Feb. 28, 2020 /PRNewswire/ -- According to a new survey from rare disease company Sobi, 28 per cent of people living with a rare condition, and their caregivers, say the disease has caused a relationship to end. 41 percent state that a rare disease has prevented them from sta...
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q4 2019 Earnings Conference Call February 13, 2020 4:00 AM ET Company Participants Guido Oelkers – Chief Executive Officer Henrik Stenqvist – Chief Financial Officer Milan Zdravkovic – Head-Research and Development ...
The following slide deck was published by Swedish Orphan Biovitrum AB (publ) in conjunction with their 2019 Q4 earnings Read more ...
STOCKHOLM , Feb. 13, 2020 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces its results for the fourth quarter and full-year 2019. Revenue growth for the full-year was 56 per cent with revenue of SEK 14,248 M . Adjusted EBITA was SEK 6,145 M , resu...
STOCKHOLM , Feb. 4, 2020 /PRNewswire/ -- On 13 February, at 08:00 CET , Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the fourth quarter and full-year 2019. Financial analysts and media are invited to participate in a telephone conference, which will inc...
STOCKHOLM , Dec. 21, 2019 /PRNewswire/ -- Dova Pharmaceuticals, Inc., a wholly owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi™) has been granted Orphan Drug Designation [1] (ODD) by the US Food and Drug Administration (FDA) for avatrombopag for the potential tre...
STOCKHOLM , Dec. 9, 2019 /PRNewswire/ -- Dova Pharmaceuticals, a wholly owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi™), presented additional analyses from the phase 3 study - core and extension phase - with avatrombopag (AVA) for the treatment of immune thrombocytop...
STOCKHOLM , Dec. 5, 2019 /PRNewswire/ -- Sobi™ and its wholly owned subsidiary Dova Pharmaceuticals, will present new data from studies with avatrombopag for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) as well as patients with chronic immune...
Biotech Pulse Biotech finally has a pulse. The improving appetite for risk has resuscitated the moribund biotechs and pharma (biopharma) groups. The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have begun their advance from their year-to-date lows recorded earlier in Octo...
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q3 2019 Earnings Conference Call October 31, 2019, 05:00 AM ET Company Participants Guido Oelkers - CEO Henrik Stenqvist - CFO Milan Zdravkovic - Head of Research & Development and Chief Medical Officer Conference Call Participant...
News, Short Squeeze, Breakout and More Instantly...
Swedish Orphan Biovit Ord Company Name:
BIOVF Stock Symbol:
OTCMKTS Market:
Repsol S.A ADR (REPYY) is expected to report $0.86 for Q1 2024 Chugai Pharmaceutical Co Ltd ADR (CHGCY) is expected to report for Q1 2024 CBIZ Inc. (CBZ) is expected to report $1.57 for Q1 2024 Financial Institutions Inc. (FISI) is expected to report $0.66 for Q1 2024 Caterpillar ...
CenterPoint Energy Inc (Holding Co) (CNP) is expected to report $0.37 for Q3 2023 The Hershey Company (HSY) is expected to report $2.47 for Q3 2023 ASE Technology Holding Co. Ltd. American Depositary Shares (each representing Two) (ASX) is expected to report for Q3 2023 Reliance Steel...
Swedish Orphan Biovitrum AB (BIOVF) is expected to report $0.09 for Q3 2023